Elpis has received a grant from Innovate UK to investigate the use of its technology for cell therapy. The project will look at the feasibility of using Elpis oligodendrocytes (a nervous system support cell) as therapy for spinal cord injury. This is a promising application of the technology for cell therapy and regenerative medicine.
“As a clinician, I see spinal cord injury patients regularly in my practice,” said Dr Mark Kotter, the CEO of Elpis, “But the technology for helping them has not yet advanced sufficiently in clinical practice. I am delighted that Elpis is at the forefront of exploring innovative approaches for helping these patients.”